

УДК 616.127-005.8-008.315-002:577.15:612.13

[https://doi.org/10.26641/2307-0404.2018.1\(part 1\).127244](https://doi.org/10.26641/2307-0404.2018.1(part 1).127244)

**O. Kuryata,
A. Zabida,
O. Sirenko**

SERUM MATRIX METALLOPROTEINASE (MMP)-2,9 ACTIVITY, GALECTIN-3 AND SYSTEMIC INFLAMMATION IN PATIENTS WITH POSTINFARCTION HEART FAILURE WITH PRESERVED EJECTION FRACTION

SE «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine»

Department of internal medicine 2

V. Vernadskyi str., 9, Dnipro, 49005, Ukraine

ДЗ «Дніпропетровська медична академія МОЗ України»

кафедра внутрішньої медицини 2

(зав. – д. мед. н., проф. О.В. Курята)

вул. В. Вернадського, 9, Дніпро, 49005, Україна

e-mail: gt1@dsma.dp.ua

Key words: *postinfarction chronic heart failure, metalloproteinase, galectin-3*

Ключові слова: *постінфарктна хронічна серцева недостатність, металопротеїнази, галектин-3*

Abstract. *Serum matrix metalloproteinase-2,9 activity, galectin-3 and systemic inflammation in patients with postinfarction heart failure with preserved ejection fraction. Kuryata O., Zabida A., Sirenko O. The available data suggest that heart failure (HF) after myocardial infarction (MI) is a very frequent event. Recent meta-analysis showed that restrictive mitral filling pattern, the most severe form of diastolic dysfunction, was presented in approximately 10% of the patients with preserved ejection fraction. In addition, restrictive pattern was associated with poor outcome. However, the true prevalence and relevance of diastolic dysfunction after MI remains to be elucidated. Objective: study was designed to evaluate the serum level of MMP-2,9, galectin-3 and C-reactive protein (C-RP) in postinfarction heart failure with preserved ejection fraction (HFpEF) patients. Methods: We divided all included patients into two main groups: 1st group – 20 patients with HFpEF and history of myocardial infarction. 2nd group – 18 patients with HFpEF and stable angina. Standard laboratory blood tests for erythrocyte sedimentation rate (ESR), C-RP, haematological parameters, lipid profile, glucose, renal and liver function tests were performed and calculated body mass index (BMI) for all patients. MMP activity assay and galectin-3 serum level was detected for all patients. Results: It was established significant differences between study groups in MMP-2, MMP-9 levels. Particularly, patients with HFpEF with MI in anamnesis had significantly higher MMP-2, MMP-9 levels on 21.8% and 20.7% respectively. The C-RP and leucocytes levels were significantly higher in 1st group pts. Significant differences in MMP-2, MMP-9 were established in 1st group patients in different age groups ($p < 0.05$) (tab. 3). The MMP 2 level was positively correlated with MMP 9 level ($R = 0.73$, $p < 0.05$), the MMP 9 level – with age ($R = 0.68$, $p < 0.05$). There were no significant differences between galectin-3 level in study group. But we estimated significant differences in galectin-3 level between 1st and 2nd subgroups ($p < 0.05$). Conclusion: Serum MMP-2, MMP-9, CRP and galectin-3 were significantly increased in pts with postinfarction heart failure with preserved ejection fraction compare to pts without myocardial infarction in anamnesis.*

Реферат. *Рівень матричних металопротеїназ-2,9, галектину-3 та системне запалення у хворих з постінфарктною серцевою недостатністю зі збереженою фракцією викиду. Курята О.В., Забіда А., Сіренко О.Ю. Літературні дані свідчать, що серцева недостатність (СН) після перенесення інфаркту міокарда (ІМ) є частотою подією. Однак поширеність і фактори виникнення діастолічної дисфункції лівого шлуночка після перенесеного ІМ залишаються маловивченими. Мета: оцінити рівні сироваткових MMP-2,9, галектину-3 та С-реактивного білка (СРП) при постінфарктній серцевій недостатності зі збереженою фракцією викиду. Матеріали та методи: у дослідження включено 38 пацієнтів з СН зі збереженою фракцією викиду віком від 40 до 80 років: 1 група (n=20) з перенесеним інфарктом міокарда в анамнезі, 2-а група (n=18) пацієнтів зі стабільною стенокардією. Виконано стандартні лабораторні аналізи крові, визначення СРП, гематологічних параметрів, ліпідного профілю, глюкози, креатиніну. Визначення активності MMP та рівня галектину-3 в сироватці крові проводилось усім пацієнтам. Результати: пацієнти з ХСН з ІМ в анамнезі мали достовірно вищий рівень MMP-2, MMP-9 на 21,8% та 20,7% відповідно ($p < 0,05$). Рівні СРП та лейкоцитів були достовірно вищими в пацієнтів 1-ї групи ($p < 0,05$). Достовірні відмінності рівней MMP-2, MMP-9 встановлені в пацієнтів з перенесеним ІМ у різних вікових групах ($p < 0,05$). Рівень MMP-2 позитивно корелював з рівнем MMP-9 ($R = 0,73$, $p < 0,05$), рівень MMP-9 – з віком ($R = 0,68$, $p < 0,05$). Встановлені достовірні відмінності між рівнем галектину-3 серед пацієнтів різного віку ($p < 0,05$). Висновок: сироваткові рівні MMP-2, MMP-9, СРП та галектину-3 були достовірно вищі у хворих з постінфарктною серцевою недостатністю зі збереженою фракцією викиду порівняно з пацієнтами без інфаркту міокарда в анамнезі.*

The available data suggest that heart failure (HF) after myocardial infarction (MI) is a very frequent event [10]. Recent meta-analysis showed that restrictive mitral filling pattern, the most severe form of diastolic dysfunction, was presented in approximately 10% of the patients with preserved ejection fraction.

In addition, restrictive pattern was associated with poor outcome [9, 10]. However, the true prevalence and relevance of diastolic dysfunction after MI remains to be elucidated. Another important issue is that the consequences of cardiac dysfunction after MI are well established, and its presence increases the risk of death by at least 3- to 4-fold [9].

The endothelium may also be central to the pathophysiology of heart failure, with endothelial cell damage or dysfunction that is probably more evident than that from vascular disease alone [1, 2, 3]. Certainly, heart failure is associated with abnormalities of thrombogenesis, leading to an increase in thrombosis related complications in this condition [10]. In HF, myocardial ischaemia features prominently (even in dilated cardiomyopathy) and severely depressed myocardial blood flow is a predictor of poor prognosis [15].

Left ventricular (LV) regional remodelling is a continuous process that last for months to years after the acute injury and which will eventually lead to the development of HF. Matrix metalloproteinases (MMPs) and tissue inhibitor metalloproteinase (TIMPs) continue to have an important role in the process of chronic LV remodelling [12, 15].

A region specific portfolio of MMPs is induced after MI and is accompanied by a decline in TIMP levels, indicative of a loss of MMP-inhibitory control. MMP-1 and MMP-9 levels are significantly reduced within the border and MI regions at 8 weeks post-MI, whereas MMP-2 levels increases substantially within the border and MI regions [15], suggesting that MMP-9 mainly is associated with early post-MI events [12, 16]. In contrast to the acute MI setting, a different set of MMPs emerges at 8 weeks after MI. Interestingly, MMP-8, localized to neutrophils, is increased by over 6-fold within the border and MI regions at 8 weeks after MI, suggesting that MMP-8 is associated with a more chronic inflammatory response [6, 12, 16]. The levels of the collagenase MMP-13, and MT1-MMP are increased by nearly 3-fold in both border and MI region 8 weeks post-MI [15]. MMP-3 is reduced within the MI region and MMP-7 falls within the border and MI regions 8 weeks post-MI. TIMP abundance decreases significantly in the border region after MI, and TIMP-1, -2 and -3 fall to undetectable levels within the MI region. Similar results are obtained by the use of a pig model of MI [12]. These data clearly

demonstrate that targeting of the regional imbalance between specific MMPs and TIMPs within the post-MI myocardium holds a therapeutic potential.

Galectin-3 is a β -galactoside-binding lectin secreted by activated macrophages, which has gained interest as at least a marker of, or possibly even a potential mediator in inflammation and fibrosis, processes that are central to the pathophysiology of LV remodeling [6, 14, 16]. Tsai et al. suggested few important clinical implications of galectin-3: 1) circulating galectin-3 was significantly higher in MI patients than in normal controls; 2) there were significant positive correlations of high circulating galectin-3 to an advanced Killip score, unstable haemodynamics requiring inotropic support, advanced HF and a high CADILLAC risk score; 3) elevated galectin-3 was proven to be a strong independent predictor of 30-day MACO (major adverse clinical outcome) among patients with STEMI undergoing primary percutaneous interventions [16]. Though, Weir et al. had demonstrated that higher galectin-3 concentrations at baseline were significantly associated with lower left ventricle ejection fraction (LVEF) at 24-week follow-up, although there was no significant relationship between galectin-3 and remodeling per se [6].

Zile et al. had demonstrated in one small series that galectin-3 levels were significantly elevated in cohort of patients with HF with HFpEF [14]. Galectin-3 might provide an early warning marker for patients who are at risk for development of HF symptoms and may allow medical intervention. According to other animal and human studies, galectin-3 in addition to clinical and some studies have shown that galectin-3 had independent prognostic value, even after correction for established risk factor such as age, sex, BNP level, renal function, and diabetes mellitus [7].

Prognostic value of galectin-3 levels in plasma appears to be much stronger in the subset of patients with HFpEF in comparison with HF with reduced ejection fraction (HFrEF) [8, 11, 13]. Also, base line levels of galectin-3 seem to be sufficient to predict outcome, because serial measurement did not increase the prognostic yield [4, 7].

Aim of our study to evaluate the serum level of MMP-2, -9, galectin-3 and C-reactive protein (CRP) in postinfarction heart failure with preserved ejection fraction patients.

MATERIALS AND METHODS

Baseline study

The study was conducted with approval from the Ethics committee at State Establishment «Dnipropetrovsk Medical Academy of Health Ministry of Ukraine» according to principles outlined in the Helsinki declaration.

Patients (n=38) included aged 40 to 80 years, 29 males and 9 females were diagnosed with (HFpEF), according to ESC guidelines (2016) [5], and their functional class according to NYHA classification for HF. All patients got standard treatment for chronic heart failure (CHF) according to ESC guidelines 2016 [10].

Patients with acute myocardial infarction (<6 months), ejection fraction (EF) $\leq 40\%$, 2nd and 3rd degree heart block, diabetes mellitus (DM), kidney insufficiency (glomerular filtration rate: $GFR \leq 30$ ml/min/1.73m²), hepatic failure, and cancer were excluded.

Standard laboratory blood tests for erythrocyte sedimentation rate, CRP, haematological parameters, lipid profile, glucose, renal and liver function tests were performed and calculated body mass index (BMI) for all patients.

Gelatin zymography (mmp activity assay)

The gelatinolytic activity was analyzed by separating serum proteins (100 μ g/track) on 7.5% SDS-PAGE gels copolymerized with gelatin (3 mg/ml). After electrophoresis, the gels were washed twice for 30 min in gold 2.5% (v/v) Triton X-100 to remove SDS, and then 5 times for 5 min in cold bi-distilled water. After washing, gels were incubated

overnight at 37 °C in developing 50 mM tris-HCl buffer (pH 7.6), containing 0.15 M NaCl, 5 mM CaCl₂, 1 mM ZnCl₂, and 0.02% Tween-80. Zymograms were stained with 0.11% Coomassie Brilliant Blue R-250 solution in 30% methanol and 10% acetic acid and destained in the same solution lack of Coomassie Blue. The final gel had a uniform blue background except in those regions to which MMPs had migrated and cleaved the substrate. The gelatinolytic activity was identified as transparent bands against the background of Coomassie Blue-stained gelatine. The zymograms were visualized and analyzed densitometrically.

All patients were assessed with galectin-3 blood levels by immunoassay analysis using the “Human Galectin-3 Platinum ELISA” kit (GmbH, Austria) on the Stat Fax 2100 (USA) immunoassay plate analyzer. The base level was taken as 0 ng/ml.

Study design

We divided all included patients into two main groups:

1st group: 20 patients with HFpEF and history of myocardial infarction.

2nd group: 18 patients with HFpEF and stable angina.

Table 1

Baseline characteristics of the study population

| Characteristics | | Patients with CHF+MI in anamnesis (n=20) | Patients with CHF+stable angina (control group) (n=18) | p |
|--|--------------------|--|--|--------|
| Gender | Males (%) | 16 (80%) | 13 (72%) | 0,2106 |
| | Females (%) | 4 (20%) | 5 (28%) | |
| Age, years | M±m | 66±9 | 70±4 | 0,2106 |
| CHF Class according to NYHA | 2 nd FC | 10 (50%) | 11 (61%) | 0,137 |
| | 3 rd FC | 10 (50%) | 7 (39%) | |
| Heart rate, beat/minute | M±m | 74±5 | 77±4 | 0,137 |
| Body mass index (BMI) | M±m | 28,00±2.10 | 30,00±2.50 | 0,202 |
| Blood glucose, mmol/L | M±m | 5.45±0.20 | 5.15±0.25 | 0,337 |
| Cholesterol, mmol/L | M±m | 5.50±1.60 | 4.95±0.25 | 0,048 |
| Triglycerides, mmol/L | M±m | 1.60±0.40 | 1.20±0.25 | 0,101 |
| ECHOCARDIOGRAPHY | | | | |
| Left ventricle ejection fraction (EF), % | | 56.00±10.00 | 61.00±11.00 | 0,136 |
| M±m | | | | |
| Left ventricle end diastolic volume (LVEDV), ml | | 137.50±45.50 | 116.00±35.00 | 0,028 |
| M±m | | | | |
| Estimated Pulmonary artery pressure sPAP, mmHg | | 30.01±9.12 | 28.24±7.14 | 0,547 |
| M±m | | | | |
| Treatment history, no, (%) | | | | |
| Beta-blockers | | 16 (80%) | 13 (72%) | |
| Renin angiotensin aldosterone system (RAAS) inhibitors | | 15 (75%) | 14 (78%) | |
| Statins | | 17 (85%) | 15 (83%) | |
| Acetylsalicylic acid (ASA) | | 19 (95%) | 16 (88%) | |

RESULTS AND DISCUSSION

Clinical characteristics of patients were summarized in table 1. HFpEF patients with MI in anamnesis had significantly higher cholesterol level and left ventricle end diastolic volume (LVEDV

($p < 0.05$). There were no significant differences between the other indicators and treatment characteristics.

Table 2

The level of MMP-2, MMP-9, galectin-3 in patients with HFpEF depending on MI anamnesis

| | 1 st group | 2 nd group | p |
|------------------------|-----------------------|-----------------------|-------|
| MMP-2 (ng/ml) M±m | 78.00±18.00 | 61,00±16.00 | 0.002 |
| MMP-9 (ng/ml) M±m | 217.50±21.50 | 172.50±6.50 | 0.003 |
| Galectin-3 (ng/ml) M±m | 8.10±4.23 | 7.04±3.12 | 0.347 |

It was established significant differences between study groups in MMP - 2, MMP-9 levels. Particularly, HFpEF patients with MI in anamnesis had significantly higher MMP-2, MMP-9 levels on 21.8% and 20.7% respectively.

The CRP and leucocytes levels were significantly higher in 1st group pts. (fig.).

Significant differences in MMP-2, MMP-9 were established in 1st group patients in different age groups ($p < 0.05$) (tab. 3). The MMP-2 level was positively correlated with MMP 9 level ($R=0.73$, $p < 0.05$), the MMP-9 level – with age ($R=0.68$, $p < 0.05$).

There were no significant differences between galectin-3 level in study group. But we estimated significant differences in galectin-3 level between 1st and 2nd subgroups ($p < 0.05$) (tab. 3).

While cytokines and MMPs have independent effects on the myocardium, past in vitro and animal

studies have identified the ability of cytokines to regulate the transcription and synthesis of various MMPs. For example, TNF over-expression in mice led to increased protein levels of MMP-2 and -9 and TIMP-1 [4, 8, 11, 17]. Regulation of MMP synthesis includes several transcription factors that are downstream of cytokine signaling. Specifically, in fibroblasts, IL-1 β stimulation has been reported to increase protein levels of MMP-2 and -9, which were attenuated with the inhibition of the transcription factor NF- κ B [11]. Similarly, IL-6 can induce the expression of MMP-1 in macrophages mediated through transcriptional regulation of activator protein-1 and NF- κ B [8]. By contrast, the anti-inflammatory cytokine IL-10 suppressed MMP-2 synthesis by signaling through the activating transcription factor 3 and binding to the cAMP-responsive element of the MMP-2 gene [4].

Table 3

The level of MMP-2, MMP-9, galectin-3 in patients with HFpEF in different age groups

| | 1 st group | | 2 nd group | |
|------------------------|-----------------------|---------------|-----------------------|-------------|
| | 40-59 y.o. | ≥ 65 y.o. | 40-59 y.o. | ≥ 65 y.o. |
| MMP-2 (ng/ml) M±m | 81.50±14.50* | 85.50±8.50* | 72.00±5.00 | 78.00±13.00 |
| MM-9 (ng/ml) M±m | 212.50±16.50* | 219.50±19.50* | 172.5±6.50 | 175.00±4.00 |
| Galectin-3 (ng/ml) M±m | 6.78±2.91 | 11.31±1.01# | 6.21±2.29 | 9.95±0.22# |

Notes: * – $p < 0.05$ between 1 and 2 groups, # – $p < 0.05$ between 40-59 y.o. and ≥ 65 y.o. groups.


Galectin-3 overexpression is also a characteristic feature of “profibrotic” M2 macrophages: naïve macrophages stimulated with interleukin-4 (IL-4) and IL-13 express higher levels of galectin-3,

together with pathophysiology of diabetes mellitus type 1 by inducing β -cell apoptosis: mice β -cells from galectin-3 were resistant to inflammation-induced cell death by counteracting mitochondrial

apoptotic pathways [6]. This is in contrast to previous research that demonstrated that intracellular galectin-3 suppresses mitochondrial apoptotic pathways by preserving mitochondrial integrity [14].

In summary, the final outcome of the fibro-inflammatory response is determined by a dynamic balance between neutrophil apoptosis, macrophage and T-cell responses, fibroblast activation and

myofibroblast persistence, and intracellular galectin-3 seems to be involved in many of these responses. However, our current understanding of galectin-3-mediated apoptotic mechanisms is limited and further studies are warranted to characterize the role of intracellular galectin-3 in apoptosis of different cell types, especially in immune-cells and collagen-producing cells.



Note. * – p<0.05

CRP, leucocytes levels in patients with HFpEF depending on MI in anamnesis

Limitation

In addition to the few number of patients included in this study, we excluded from our study patients with acute coronary artery diseases and acute heart failure, because of this our results apply only to the patients with chronic coronary artery diseases and chronic heart failure.

There are many matrix metalloproteinases which involved in all cardiovascular diseases, but in our study we measured levels and activity of only MMP-2 and MMP-9.

CONCLUSION

1. Serum MMP-2, MMP-9, CRP and galectin-3 were significantly increased in pts with postinfarction heart failure with preserved ejection fraction comparing to pts without myocardial infarction in anamnesis.

2. Increased level of serum MMP-2, MMP-9, CRP were positively correlated with age reaching maximal concentration with age ≥ 65 years old in pts with postinfarction heart failure with preserved ejection fraction.

REFERENCES

1. Kuryata OV, Sirenko O. [Daily Blood Pressure, lipid profile of blood in patients with arterial hypertension in combination with rheumatoid arthritis and efficacy of atorvastatin]. *Simeyna medytsyna*. 2015;3 (59):155-9. Ukrainian. doi: 10.22141/2224-1485.6.50.2016.89771
2. Kuryata OV, Zabida A, Chvora DL. [Risk factors, conditions of cardiohemodynamics and renal function in

- patients with chronic heart failure and myocardial infarction in anamnesis]. *Medicni perspektivi*. 2017;XXII(3):25-32. Ukrainian. <https://doi.org/10.26641/2307-0404.2017.3.111914>
3. Kuryata AV, Lysunets TK, Noda OYu. [The effectiveness of cocarina in complex therapy in patients with systemic connective tissue diseases with myocardial

damage and manifestations of heart failure]. *Mezhdunarodnyy meditsinskiy zhurnal*. 2012;2:44-49. Russian.

4. Kawamura N, Kubota T, Kawano S, et al. Blockade of NF- κ B improves cardiac function and survival without affecting inflammation in TNF- α -induced cardiomyopathy. *Cardiovasc. Res.* 2005;66:520-9.

5. Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European Heart Journal*. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehs104

6. Weir RA, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. *Circ. Heart Fail.* 2013;492-8. doi: 10.1161/CIRCHEARTFAILURE.112.000146

7. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. *European Journal of Heart Failure*. 2009;11(9):811-7. doi: 10.1093/eurjhf/hfp097.

8. Saksida T, Nikolic I, Vujicic M, et al. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. *J Cell Physiol*. 2013;228:1568-76. doi: 10.1002/jcp.24318

9. Gheorghide M, Fonarow GC. Management of post-myocardial infarction patients with left ventricular systolic dysfunction. *Am. J. Med.* 2007;120:109-20. doi: 10.1016/j.amjmed.2005.08.010

10. Møller JE, Whalley GA, Dini FL, et al. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction. *Circulation*.

2008;117:2591-8. doi: 10.1161/CIRCULATIONAHA.107.738625. Epub 2008 May 12.

11. Sundararaj KP, Samuvel DJ, Sanders JJ, et al. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glucose. *J. Biol. Chem.* 2009;284:13714-24.

12. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. *Circulation*. 2003;107(4):618-25.

13. Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. *PLoS ONE*. 2013;8(3):e58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5.

14. Zile MR, De Santis SM, Baicu CF, et al. Plasma galectin-3 levels in patients with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition. *Circulation*. 2010;122:A12433.

15. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. *Circulation*. 2003;107(22):2857-63. doi: 10.1161/01.CIR.0000068375.40887.FA

16. Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. *J. Atheroscler. Thromb.* 2012;19:1073-82.

17. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1 β . *J. Biol. Chem.* 2004;279:39513-9.

СПИСОК ЛІТЕРАТУРИ

1. Курята О.В. Добовий профіль артеріального тиску, ліпідний спектр крові у хворих на артеріальну гіпертензію в поєднанні з ревматоїдним артритом та ефективність застосування аторвастатину / О.В. Курята, О.Ю. Сіренко // *Сімейна медицина*. – 2015. – № 3 (59). – С. 155-159. doi: 10.22141/2224-1485.6.50.2016.89771

2. Курята О.В. Фактори ризику, станостія кардіогемодинаміки і функція почек у пацієнтів с хронической сердечной недостаточностью и инфарктом миокарда в анамнезе / О. В. Курята, А. Забида, Д. Л. Чвора // *Медичні перспективи*. – 2017. – Т. XXII, № 3. – С. 25-32. <https://doi.org/10.26641/2307-0404.2017.3.111914>

3. Курята О.В. Эффективность кокарнита в комплексной терапии у пациентов с системными заболеваниями соединительной ткани с поражением миокарда и проявлениями сердечной недостаточности / А.В. Курята, Т.К. Лысунец, О.Ю. Нода // *Международ. мед. журнал*. – 2012. – № 2. – С. 44-49.

4. Blockade of NF- κ B improves cardiac function and survival without affecting inflammation in TNF- α -induced cardiomyopathy / N. Kawamura, T. Kubota,

S. Kawano [et al.] // *Cardiovascular Res.* – 2005. – Vol. 66. – P. 520-529.

5. ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC / P. Ponikowski [et al.] // *Eur. Heart J.* – 2016. – Vol. 37, N 27. – P. 2129-200. doi: 10.1093/eurheartj/ehs104

6. Galectin-3 and cardiac function in survivors of acute myocardial infarction / R.A. Weir, C.J. Petrie, C.A. Murphy [et al.] // *Circulation Heart Failure*. – 2013. – P. 492-498. doi: 10.1161/CIRCHEARTFAILURE.112.000146

7. Galectin-3: a novel mediator of heart failure development and progression / R.A. de Boer, A.A. Voors, P. Muntendam [et al.] // *Eur. J. Heart Failure*. – 2009. – Vol. 11, N 9. – P. 811-817. doi: 10.1093/eurjhf/hfp097

8. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro / T. Saksida, I. Nikolic, M. Vujicic [et al.] // *J. Cell Physiology*. – 2013. – Vol. 228. – P. 1568-76. doi: 10.1002/jcp.24318

9. Gheorghide M. Management of post-myocardial infarction patients with left ventricular systolic dysfunction / M. Gheorghide, G. C. Fonarow // *Am. J. Medicine.* – 2007. – Vol. 120. – P. 109-120. doi: 10.1016/j.amjmed.2005.08.010

10. Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis: Meta-Analysis Research Group in Echocardiography acute myocardial infarction / J.E. Møller, G.A. Whalley, F.L. Dini [et al.] // *Circulation.* – 2008. – Vol. 117. – P. 2591-2598. doi: 10.1016/j.amjmed.2005.08.010

11. Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture-crosstalking between fibroblasts and u937 macrophages exposed to high glucose / K. P. Sundararaj, D. J. Samuvel, J. J. Sanders, [et al.] // *J. Biology Chemistry.* – 2009. – Vol. 284. – P. 13714-13724.

12. Myocardial infarct expansion and matrix metalloproteinase inhibition / R. Mukherjee, T.A. Brinsa, K.B. Dowdy [et al.] // *Circulation.* – 2003. – Vol. 107, N 4. – P. 618-625.

13. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12

randomized trials / G. Savarese, B. Trimarco, S. Delle-grottaglie [et al.] // *PLoS ONE.* – 2013. – Vol.8, N 3. – e58287. doi: 10.1371/journal.pone.0058287, Epub 2013 Mar 5.

14. Plasma galectin- 3 levels in patients with structural and clinical manifestation of hypertensive heart disease: relationship to determination of matrix composition / M.R. Zile, S.M. De Santis, C.F. Baicu [et al.] // *Circulation.* – 2010. – Vol. 122. – A12433.

15. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodelling / E.M. Wilson, S.L. Moainie, J.M. Baskin [et al.] // *Circulation.* – 2003. – Vol. 107, N 22. – P. 2857-63. doi: 10.1161/01.CIR.0000068375.40887.FA

16. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention / T.H. Tsai, P.H. Sung, L.T. Chang [et al.] // *J. Atherosclerosis, Thrombosis.* – 2012. – Vol. 19. – P. 1073-1082.

17. Xie Z. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin- 1 β / Z. Xie, M. Singh, K. Singh // *J. Biology Chemistry.* – 2004. – Vol. 279. – P. 39513-39519. doi: 10.1002/jcp.24318



УДК 616.2:616.61-036.1-089.843-072.7:615.37

[https://doi.org/10.26641/2307-0404.2018.1\(part 1\).127245](https://doi.org/10.26641/2307-0404.2018.1(part 1).127245)

О.В. Курята¹,
О.О. Штена¹,
О.В. Галушак²

ФУНКЦІЯ ЗОВНІШНЬОГО ДИХАННЯ У ХВОРИХ ПІСЛЯ ТРАНСПЛАНТАЦІЇ НИРКИ В УМОВАХ ІМУНОСУПРЕСИВНОЇ ТЕРАПІЇ

ДЗ «Дніпропетровська медична академія МОЗ України»¹
кафедра внутрішньої медицини 2

(зав. – д. мед. н., проф. О.В. Курята)

вул. В. Вернадського, 9, Дніпро, 49044, Україна

КЗ «Дніпропетровська обласна клінічна лікарня ім. І.І. Мечникова»²

відділення діалізу (хронічного гемодіалізу та амбулаторного гемодіалізу)

пл. Соборна, 14, Дніпро, 49005, Україна

SE “Dnipropetrovsk medical academy of Health Ministry of Ukraine”¹

Department of internal medicine 2

V. Vernadsky str., 9, Dnipro, 49044, Ukraine

ME “Dnipropetrovsk Regional Clinical Hospita. named after I.I. Mechnikov”²

Department dialysis (hemodialysis and chronic ambulatory hemodialysis)

Soborna sq., 14, Dnipro, 49005, Ukraine

e-mail: shtepaolha@gmail.com

Ключові слова: функція зовнішнього дихання, трансплантація нирки, імуносупресивна терапія, циклоспорин, такролімус

Key words: function of external respiration, kidney transplantation, immunosuppressive therapy, cyclosporine, tacrolimus